Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
The Prostate|May 28, 2015
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determinationChanning J Paller, Michelle A Rudek, Xian C Zhou, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Molecular Cancer Therapeutics|September 18, 2020
Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate CancerOliver C Rogers, Lizamma Antony, Oren Levy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2009
Knockin of mutant PIK3CA activates multiple oncogenic pathwaysJohn P Gustin, Bedri Karakas, Michele B Weiss, et al.
JAMA Oncology|August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled TrialCatherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
The Prostate|May 28, 2015
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determinationChanning J Paller, Michelle A Rudek, Xian C Zhou, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Molecular Cancer Therapeutics|September 18, 2020
Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate CancerOliver C Rogers, Lizamma Antony, Oren Levy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2009
Knockin of mutant PIK3CA activates multiple oncogenic pathwaysJohn P Gustin, Bedri Karakas, Michele B Weiss, et al.
JAMA Oncology|August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled TrialCatherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
Pageof 16